JP2018529656A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018529656A5 JP2018529656A5 JP2018509504A JP2018509504A JP2018529656A5 JP 2018529656 A5 JP2018529656 A5 JP 2018529656A5 JP 2018509504 A JP2018509504 A JP 2018509504A JP 2018509504 A JP2018509504 A JP 2018509504A JP 2018529656 A5 JP2018529656 A5 JP 2018529656A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- cancer
- dll3
- cancer cells
- ihc assay
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 206010028980 Neoplasm Diseases 0.000 claims 14
- 201000011510 cancer Diseases 0.000 claims 14
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 102100036466 Delta-like protein 3 Human genes 0.000 claims 8
- 101000928513 Homo sapiens Delta-like protein 3 Proteins 0.000 claims 8
- 238000003556 assay Methods 0.000 claims 8
- 229940127276 delta-like ligand 3 Drugs 0.000 claims 8
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 1
- 229960003957 dexamethasone Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229910052697 platinum Inorganic materials 0.000 claims 1
- 238000011518 platinum-based chemotherapy Methods 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562207830P | 2015-08-20 | 2015-08-20 | |
| US62/207,830 | 2015-08-20 | ||
| US201662323998P | 2016-04-18 | 2016-04-18 | |
| US62/323,998 | 2016-04-18 | ||
| US201662373906P | 2016-08-11 | 2016-08-11 | |
| US62/373,906 | 2016-08-11 | ||
| PCT/US2016/047870 WO2017031458A2 (en) | 2015-08-20 | 2016-08-19 | Anti-dll3 antibody drug conjugates and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018529656A JP2018529656A (ja) | 2018-10-11 |
| JP2018529656A5 true JP2018529656A5 (cg-RX-API-DMAC7.html) | 2019-09-26 |
Family
ID=58052015
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018509504A Ceased JP2018529656A (ja) | 2015-08-20 | 2016-08-19 | 抗ｄｌｌ３抗体薬物コンジュゲートおよび使用方法 |
Country Status (20)
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10202002131PA (en) | 2015-05-21 | 2020-05-28 | Harpoon Therapeutics Inc | Trispecific binding proteins and methods of use |
| CN109862919A (zh) * | 2016-10-11 | 2019-06-07 | 免疫医疗有限公司 | 抗体-药物缀合物联合免疫介导的治疗剂 |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| EA202090817A1 (ru) | 2017-10-13 | 2020-09-08 | Харпун Терапьютикс, Инк. | Триспецифические белки и способы их применения |
| WO2019137548A1 (en) * | 2018-01-15 | 2019-07-18 | Nanjing Legend Biotech Co., Ltd. | Antibodies and variants thereof against tigit |
| SG11202011330PA (en) | 2018-05-14 | 2020-12-30 | Harpoon Therapeutics Inc | Binding moiety for conditional activation of immunoglobulin molecules |
| WO2020061482A1 (en) | 2018-09-21 | 2020-03-26 | Harpoon Therapeutics, Inc. | Egfr binding proteins and methods of use |
| EP3908679A1 (en) * | 2019-03-08 | 2021-11-17 | OncoLab Diagnostics GmbH | Cancer diagnosis and prognosis |
| MX2021015095A (es) * | 2019-06-07 | 2022-03-22 | Mythic Therapeutics Inc | Construcciones de proteínas de unión a antígenos y usos de estos. |
| EP4056592A4 (en) * | 2019-11-08 | 2024-03-20 | Jiangsu Simcere Pharmaceutical Co., Ltd. | ANTIBODY AGAINST HUMAN PROGRAMMED CELL DEATH LIGAND 1 (PD-L1) AND USE THEREOF |
| EP3819312A1 (en) * | 2019-11-10 | 2021-05-12 | Amgen, Inc | Dosing regimen for anti-dll3 agents |
| CN115003325A (zh) * | 2019-12-20 | 2022-09-02 | 安托斯治疗股份有限公司 | 因子xi/xia抗体的药物制剂和剂量方案 |
| WO2021226204A2 (en) * | 2020-05-05 | 2021-11-11 | Oncorus, Inc. | Anti-dll3 antibodies and methods of use |
| MX2023008261A (es) | 2021-01-13 | 2023-09-12 | Memorial Sloan Kettering Cancer Center | Conjugado de anticuerpo-derivado de pirrolobenzodiazepina. |
| JP2024503658A (ja) | 2021-01-13 | 2024-01-26 | メモリアル スローン－ケタリング キャンサー センター | 抗ｄｌｌ３抗体－薬物コンジュゲート |
| CN117377488A (zh) * | 2021-05-10 | 2024-01-09 | 安进公司 | 靶向dll3和pd-1的组合疗法的给药方案 |
| CN116271079B (zh) * | 2021-07-30 | 2025-11-14 | 上海复旦张江生物医药股份有限公司 | 一种抗dll3抗体及其制备方法、其药物偶联物和应用 |
| AU2022317608A1 (en) * | 2021-07-30 | 2024-03-14 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Anti-dll3 antibody and preparation method therefor, drug conjugate and application thereof |
| WO2023034566A1 (en) * | 2021-09-02 | 2023-03-09 | Memorial Sloan-Kettering Cancer Center | Anti-dll3 antibodies and uses thereof |
| PE20241133A1 (es) * | 2021-09-17 | 2024-05-24 | Wuxi Biologics Ireland Ltd | Moleculas de union a d3 y usos de estas |
| CN114230666B (zh) * | 2021-12-20 | 2022-09-02 | 南京诺唯赞生物科技股份有限公司 | 一种t7 rna聚合酶的单克隆抗体及其制备方法 |
| TW202346346A (zh) * | 2021-12-23 | 2023-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 抗ｄｌｌ３抗體、其抗體－藥物偶聯物及其醫藥用途 |
| CN114369162B (zh) * | 2021-12-28 | 2023-05-30 | 合肥天港免疫药物有限公司 | 抗体及其应用 |
| US20250154247A1 (en) * | 2022-02-23 | 2025-05-15 | Amgen Inc. | Cancer treatment targeting dll3 |
| CN114573698B (zh) * | 2022-03-16 | 2023-01-06 | 沈阳三生制药有限责任公司 | 一种FcRn抗原结合蛋白及其制备方法和应用 |
| AU2023330110A1 (en) | 2022-08-22 | 2025-03-06 | Abdera Therapeutics Inc. | Dll3 binding molecules and uses thereof |
| CN116253798B (zh) * | 2022-12-15 | 2023-10-27 | 华中农业大学 | 一株针对猪δ冠状病毒S1蛋白构象表位的中和性单克隆抗体 |
| CN116217715B (zh) * | 2023-01-17 | 2023-08-15 | 山东农业大学 | 基于识别不同抗原决定簇的马铃薯y病毒单克隆抗体的组合及其应用 |
| WO2024179470A1 (zh) * | 2023-02-27 | 2024-09-06 | 苏州盛迪亚生物医药有限公司 | 抗dll3抗体、其抗体-药物偶联物及其医药用途 |
| WO2025190281A1 (en) * | 2024-03-11 | 2025-09-18 | Lepu Biopharma Co., Ltd. | Anti-dll3 antibodies and uses thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3095797B1 (en) * | 2012-02-24 | 2020-05-20 | AbbVie Stemcentrx LLC | Anti dll3 antibodies and methods of use thereof |
| SG10201801444WA (en) * | 2012-02-24 | 2018-04-27 | Abbvie Stemcentrx Llc | Anti sez6 antibodies and methods of use |
| EP2839860B1 (en) * | 2012-10-12 | 2019-05-01 | MedImmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| US9968687B2 (en) * | 2013-02-22 | 2018-05-15 | Abbvie Stemcentrx Llc | Anti-DLL3 antibody drug conjugates |
| JP2016518382A (ja) * | 2013-04-26 | 2016-06-23 | ピエール、ファーブル、メディカマン | Ａｘｌ抗体薬物複合体および癌の治療のためのその使用 |
| CN105873612A (zh) * | 2013-08-28 | 2016-08-17 | 施特姆森特克斯股份有限公司 | 改造的抗-dll3缀合物以及应用方法 |
| BR112016004242A8 (pt) * | 2013-08-28 | 2018-06-12 | Stemcentrx Inc | Métodos para conjugação sítio-específica de anticorpos e composições |
| EP3054983B1 (en) * | 2013-10-11 | 2019-03-20 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| WO2015052535A1 (en) * | 2013-10-11 | 2015-04-16 | Spirogen Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
| EP3054984A1 (en) * | 2013-10-11 | 2016-08-17 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| EP3054985B1 (en) * | 2013-10-11 | 2018-12-26 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
-
2016
- 2016-08-19 HK HK18116192.2A patent/HK1257056A1/zh unknown
- 2016-08-19 CN CN201680061029.8A patent/CN108136015A/zh active Pending
- 2016-08-19 PE PE2018000271A patent/PE20181292A1/es unknown
- 2016-08-19 BR BR112018003269A patent/BR112018003269A2/pt not_active Application Discontinuation
- 2016-08-19 KR KR1020187007525A patent/KR20180041717A/ko not_active Withdrawn
- 2016-08-19 WO PCT/US2016/047870 patent/WO2017031458A2/en not_active Ceased
- 2016-08-19 EA EA201890530A patent/EA201890530A1/ru unknown
- 2016-08-19 US US15/753,509 patent/US20180243435A1/en not_active Abandoned
- 2016-08-19 CA CA2996165A patent/CA2996165A1/en not_active Abandoned
- 2016-08-19 AU AU2016308365A patent/AU2016308365A1/en not_active Abandoned
- 2016-08-19 EP EP16837930.3A patent/EP3337517A4/en not_active Withdrawn
- 2016-08-19 MX MX2018002166A patent/MX2018002166A/es unknown
- 2016-08-19 JP JP2018509504A patent/JP2018529656A/ja not_active Ceased
- 2016-08-19 TW TW105126609A patent/TW201718026A/zh unknown
- 2016-08-19 UY UY0001036862A patent/UY36862A/es not_active Application Discontinuation
-
2018
- 2018-02-20 PH PH12018500380A patent/PH12018500380A1/en unknown
- 2018-02-20 CL CL2018000458A patent/CL2018000458A1/es unknown
- 2018-02-20 IL IL257645A patent/IL257645A/en unknown
- 2018-02-20 CO CONC2018/0001624A patent/CO2018001624A2/es unknown
- 2018-02-28 ZA ZA2018/01401A patent/ZA201801401B/en unknown
- 2018-12-21 CL CL2018003758A patent/CL2018003758A1/es unknown